MRA(Tocilizumab)
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Rheumatoid Arthritis
Conditions
Rheumatoid Arthritis
Trial Timeline
Aug 1, 2001 → Jun 1, 2009
NCT ID
NCT00144651About MRA(Tocilizumab)
MRA(Tocilizumab) is a phase 2 stage product being developed by Chugai Pharmaceutical for Rheumatoid Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00144651. Target conditions include Rheumatoid Arthritis.
What happened to similar drugs?
20 of 20 similar drugs in Rheumatoid Arthritis were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00380601 | Phase 3 | Completed |
| NCT00144586 | Phase 3 | Completed |
| NCT00144625 | Phase 3 | Completed |
| NCT00144560 | Pre-clinical | Completed |
| NCT00144573 | Pre-clinical | Completed |
| NCT00144664 | Phase 3 | Completed |
| NCT00144612 | Phase 3 | Completed |
| NCT00144547 | Phase 3 | Completed |
| NCT00144651 | Phase 2 | Completed |
Competing Products
20 competing products in Rheumatoid Arthritis